R. Jude Samulski Inventions Information

Richard Jude Samulski is an American scientist, inventor, and academic known for his pioneering work in gene therapy and adeno-associated virus vectors in the fields of molecular virology and pharmacology, and holds patents related to AAV vector technology.

Samulski is director of the UNC Gene Therapy Center and a member of the UNC Lineberger Comprehensive Cancer Center. Samulski completed his Ph.D. at the University of Florida (1982) and his B.S. at Clemson University (1976). R. Jude Samulski co-founded biotechnology companies active in gene therapy and AAV commercialization, including AskBio (Asklepios BioPharmceutical Inc.), NanoCor Therapeutics, Inc. and Bamboo Therapeutics, Inc.

In 2008, Samulski was the first person to receive the “Outstanding Achievement Award” by the American Society of Gene and Cell Therapy, which recognized his “lifetime of significant scientific contributions to the field of gene therapy.” Samulski was President of the American Society of Gene and Cell Therapy in 2011. His contributions to scientific literature include 208 academic publications, and broadly cited by their scholarly discipline with 3,158 patent citations and 17,140 scholarly citations.

Samulski’s research has focused on the study of the human non-pathogenic parvovirus adeno-associated virus (AAV) and its use in gene therapies. In the 1980s, as a graduate student, he pioneered the use of AAV as a vector for therapeutic genes. His work demonstrated AAV2 as a viral vector for gene therapy which led to the first U.S. Patent for inserting genes into AAV.

Samulski has been named as a co-inventor for patents related to gene delivery which relate to adeno-associated virus vectors. This technique has been used in gene therapy clinical trials for cystic fibrosis, Duchenne muscular dystrophy,haemophilia and Parkinson’s disease, and the foundation for gene therapy research and development in the bioscience industry and academic institutions such as UNC

In 2014, Pfizer acquired Bamboo Therapeutics, a company founded in 2014 to "advance the work of Dr. Richard Jude Samulski."

In 2019, Baxter International acquired programs developed by AskBio, a company he co-founded with Xiao Xiao.

Complete article available at this page.